Logo image
Back
Inflammatory myopathies: How to treat the difficult cases
Journal article   Peer reviewed

Inflammatory myopathies: How to treat the difficult cases

F.L. Mastaglia and P.J. Zilko
Journal of Clinical Neuroscience, Vol.10(1), pp.99-101
2003
DOI: https://doi.org/10.1016/S0967-5868(02)00271-0
url
Link to Published Version *Subscription may be requiredView

Abstract

The initial approach to the treatment of patients with inflammatory myopathy is critical in determining the subsequent course and outcome. Prolonged administration of high doses of corticosteroids should be avoided and a second-line agent such as methotrexate or azathioprine should be introduced earlier rather than later. Intravenous immunoglobulin therapy has an important place if the myositis remains active, particularly in patients with dermatomyositis, and is the treatment of choice in patients with immunodeficiency who are not controlled by corticosteroids. In more resistant cases of polymyositis or dermatomyositis it may be necessary to use cyclophosphamide, cyclosporin or the promising newer immunosuppressive agents mycophenolate mofetil or tacrolimus to achieve disease control. The treatment of inclusion body myositis remains unsatisfactory but a trial of prednisolone and methotrexate is warranted in selected patients.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

59 Record Views
26 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.106 Rheumatology
1.106.1684 Dermatomyositis
Web Of Science research areas
Clinical Neurology
Neurosciences
ESI research areas
Neuroscience & Behavior
Logo image